Arrowhead Research | ARWR - Operating Profit


Arrowhead Research reported $-170.09M in Operating Profit for its fiscal quarter ending in June of 2026.





Operating Profit Change Date
Agios Pharmaceuticals USD -110.55M 527K Jun/2026
Alnylam Pharmaceuticals USD 179.66M 67.06M Sep/2026
Anika Therapeutics USD 646K 3.88M Dec/2025
Arrowhead Research USD -170.09M 28.83M Jun/2026
Heron Therapeutics USD 38K 3.83M Dec/2025
Incyte USD -707.47M 1.41B Sep/2026
Ionis Pharmaceuticals USD -130M 27.71M Sep/2026
Ligand Pharmaceuticals USD 54.53M 2.1M Sep/2026
Merck USD 7.33B 6.49B Sep/2026
Moderna USD 130M 945M Sep/2026
Nektar Therapeutics USD -38.26M 19.17M Mar/2026
Novartis USD 5.14B 392M Sep/2026
Sarepta Therapeutics USD -9.04M 22.33M Sep/2026
TG Therapeutics USD 85.9M 64.22M Sep/2026
Ultragenyx Pharmaceutical USD -110M 35M Sep/2026
Vertex Pharmaceuticals USD 1.26B 11.3M Sep/2026
Xencor USD -36.6M 41.26M Jun/2026